Chen Q, Ishii K, Mori H, Nishijima A, Arai S, Miyazaki T, Rosenthal PB. Cryo-EM reveals structural basis for human AIM/CD5L recognition of polymeric immunoglobulin M. Nat Commun. 2024, 15, 9387.

Yasuda K, Shimodan S, Maehara N, Hirota A, Iijima R, Nishijima A, Mori H, Toyama R, Ito A, Yoshikawa Y, Arai S, Miyazaki T. AIM/CD5L ameliorates autoimmune arthritis by promoting removal of inflammatory DAMPs at the lesions. J Autoimmun. 2023, 142, 103149.

Nemoto H, Honjo M, Arai S, Miyazaki T, Aihara M. Apoptosis inhibitor of macrophages/CD5L enhances phagocytosis in the trabecular meshwork cells and regulates ocular hypertension. J Cell Physiol. 2023, 238, 2451–2467.

Takimoto-Sato M, Suzuki M, Kimura H, Ge H, Matsumoto M, Makita H, Arai S, Miyazaki T, Nishimura M, Konno S. Apoptosis inhibitor of macrophage (AIM)/CD5L is involved in the pathogenesis of COPD. Respir Res. 2023, 24, 201.

Okanoue T, Yamaguchi K, Shima T, Mitsumoto Y, Katayama T, Okuda K, Mizuno M, Seko Y, Moriguchi M, Itoh Y, Miyazaki T. Artificial intelligence/neural network system that accurately diagnoses hepatocellular carcinoma in nonalcoholic steatohepatitis. Hepatol Res. 2023, 53, 1213-1223..

Okanoue T, Yamaguchi K, Shima T, Mitsumoto Y, Mizuno M, Katayama T, Seko Y, Moriguchi M, Umemura A, Itoh Y, Miyazaki T. The serum levels of IgM-free apoptosis inhibitor of macrophage /CD5L as a predictive and early diagnostic marker for NASH-associated hepatocellular carcinoma. Hepatol Res. 2022, 52, 998-1008.

Matsuura K, Maehara N, Hirota A, Eguchi A, Yasuda K, Taniguchi K, Nishijima A, Matsuhashi N, Shiga Y, Ishii R, Iguchi Y, Tanabe K, Arai S, Miyazaki T. Two independent modes of kidney stone suppression achieved by AIM/CD5L and KIM-1. Commun Biol. 2022, 5, 783.

Shimizu T, Sawada T, Asai T, Kanetsuki Y, Hirota J, Moriguchi M, Nakajima T, Miyazaki T, Okanoue T. Hepatocellular carcinoma diagnosis using a novel electrochemiluminescence immunoassay targeting serum IgM-free AIM. Clin J Gastroenterol. 2022, 15, 41-51.

Wang C-T, Tezuka T, Takeda N, Araki K, Arai S, Miyazaki T. High salt exacerbates acute kidney injury by disturbing the activation of CD5L/apoptosis inhibitor of macrophage (AIM) protein. PLoS One. 2021, 16, e0260449.

Maehara N, Taniguchi K, Okuno A, Ando H, Hirota A, Li Z, Wang C-T, Arai S, Miyazaki T. AIM/CD5L attenuates DAMPs in the injured brain and thereby ameliorates ischemic stroke. Cell Rep. 2021, 36, 109693.

Lee JY, Arumugarajah S, Lian D, Maehara N, Haig AR, Suri RS, Miyazaki T, Gunaratna L. Recombinant apoptosis inhibitor of macrophage protein reduces delayed graft function in a murine model of kidney transplantation. PLoS One. 2021, 16, e0249838.

Hasegawa H, Mizoguchi I, Orii N, Inoue S, Katahira Y, Yoneto T, Xu M, Miyazaki T, Yoshimoto T. IL-23p19 and CD5 antigen-like form a possible novel heterodimeric cytokine and contribute to experimental autoimmune encephalomyelitis development. Sci Rep. 2021, 11, 5266.

Takahata A, Arai S, Hiramoto E, Kitada K, Makita Y, Suzuki H, Nakata J, Araki K, Miyazaki T, Suzuki Y. Crucial role of AIM/CD5L in the development of glomerular inflammation in IgA Nephropathy. J Am Soc Nephrol. 2020, 31, 2013-2024.

Takano T, Bareke E, Takeda N, Aoudjit L, Baldwin C, Pisano P, Matsuda J, El Andalousi J, Muhtadie L, Bernard C, Majewski J, Miyazaki T, Yamamura, K-I, Gupta, IR. Recessive mutation in CD2AP causes focal segmental glomerulosclerosis in humans and mice. Kidney Int. 2019, 95, 57-61.

Komatsu G, Nonomura T, Sasaki M, Ishida Y, Arai S, Miyazaki T. AIM-deficient mouse fed a high-trans fat, high-cholesterol diet: a new animal model for nonalcoholic fatty liver disease. Exp Anim. 2019, 68, 147–158.

Sugisawa R, Komatsu G, Hiramoto E, Takeda N, Yamamura K-I, Arai S, Miyazaki T. Independent modes of disease repair by AIM protein distinguished in AIM-felinized mice. Sci Rep. 2018, 8, 13157.

Hiramoto E, Tsutsumi A, Suzuki R, Matsuoka S, Arai S, Kikkawa M, Miyazaki T. The IgM pentamer is an asymmetric pentagon with an open groove that binds the AIM protein. Sci Adv. 2018, 4, eaau1199.

Miyazaki T. Homage to Mechnikov - the phagocytic system: past and present. Semin Immunopathol. 2018, 40, 519-521.

Arai S, Miyazaki T. A scavenging system against internal pathogens promoted by the circulating protein apoptosis inhibitor of macrophage (AIM). Semin Immunopathol. 2018, 40, 567-575.

Koyama N, Yamazaki T, Kanetsuki Y, Hirota J, Asai T, Mitsumoto Y, Mizuno M, Shima T, Kanbara Y, Arai S, Miyazaki T, Okanoue T. Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma. J Gastroenterol. 2018, 53, 770-779.

Miyazaki T, Yamazaki T, Sugisawa R, Gershwin ME, Arai S. AIM associated with the IgM pentamer: attackers standing by on an aircraft carrier. Cell Mol Immunol. 2018, 15, 563-574.

Tomita T, Arai S, Kitada K, Mizuno M, Suzuki Y, Sakata F, Nakano D, Hiramoto E, Takei Y, Maruyama S, Nishiyama A, Matsuo S, Miyazaki T, Ito Y. Apoptosis inhibitor of macrophage ameliorates fungus-induced peritoneal injury model in mice. Sci Rep. 2017, 7, 6450.

Matsumoto A, Taniguchi K, Takeda N, Yamamura-KI, Arai S, Miyazaki T. Inflammatory and anti-inflammatory states of adipose tissue in transgenic mice bearing a single TCR. Int Immunol. 2017, 29, 21-30.

Oshima M, Iwata Y, Furuichi K, Sakai N, Shimizu M, Hara A, Kitajima S, Toyama T, Shinozaki Y, Sagara A, Umeda E, Kaneko S, Arai S, Miyazaki T, Wada T. Association of apoptosis inhibitor of macrophage (AIM) expression with urinary protein and kidney dysfunction. Clin Exp Nephrol. 2017, 21, 35-42.

Yamazaki T, Sugisawa R, Hiramoto E, Takai R, Matsumoto A, Senda Y, Nakashima K, Nelson P S, Lucas JM, Morgan A, Li Z, Yamamura KI, Arai S, Miyazaki T. A proteolytic modification of AIM promotes its renal excretion. Sci Rep. 2016, 6, 38762.

Ozawa T, Maehara N, Kai T, Arai S, Miyazaki T. Dietary fructose-induced hepatocellular carcinoma development manifested in mice lacking apoptosis inhibitor of macrophage (AIM) Genes Cells. 2016, 21, 1320-1332.

Sugisawa R, Hiramoto E, Matsuoka S, Iwai S, Takai R, Yamazaki T, Mori N, Okada Y, Takeda N, Yamamura K-I, Arai T, Arai S, Miyazaki T. Impact of feline AIM on the susceptibility of cats to renal disease. Sci Rep. 2016, 6, 35251.

Arai S, Kitada K, Yamazaki T, Takai R, Zhang X, Tsugawa Y, Sugisawa R, Matsumoto A, Mori M, Yoshihara Y, Doi K, Maehara N, Kusunoki S, Takahata A, Noiri E, Suzuki Y, Yahagi N, Nishiyama A, Gunaratnam L, Takano T, Miyazaki T. Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice. Nat Med. 2016, 22, 183-193.

Wang C, Yosef N, Gaublomme J, Wu C, Lee Y, Clish CB, Kaminski J, Xiao S, Meyer Zu Horste G, Pawlak M, Kishi Y, Joller N, Karwacz K, Zhu C, Ordovas-Montanes M, Madi A, Wortman I, Miyazaki T, Sobel RA, Park H, Regev A, Kuchroo VK. CD5L/AIM Regulates Lipid Biosynthesis and Restrains Th17 Cell Pathogenicity. Cell. 2015, 163, 1413-1427.

Miyazaki T, Arai S. A defense system against multiple diseases via biological garbage clearance mediated by soluble scavenger proteins. Inflamm Regen. 2015, 35, 203-209.

Miyazaki T, Arai S. Tricking an ancient immune function to eradicate hepatocellular carcinoma. Mol Cell Oncol. 2015, 2, e985915.

Yamazaki T, Mori M, Arai S, Tateishi R, Abe M, Ban M, Nishijima A, Maeda M, Asano T, Kai T, Izumino K, Takahashi J, Aoyama K, Harada S, Takebayashi T, Gunji T, Ohnishi S, Seto S, Yoshida Y, Hiasa Y, Koike K, Yamamura K, Inoue K, Miyazaki T. Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans. PLoS One. 2014, 9, e109123.

Maehara N, Arai S, Mori M, Iwamura Y, Kurokawa J, Kai T, Kusunoki S, Taniguchi K, Ikeda K, Ohara O, Yamamura K, Miyazaki T. Circulating AIM prevents hepatocellular carcinoma through complement activation. Cell Rep. 2014, 9, 61-74.

Tomura S, Uchida M, Yonezawa T, Arai S, Miyazaki T, Tamahara, Matsuki N. Molecular cloning and gene expression of canine apoptosis inhibitor of macrophage. J Vet Med Sci. 2014, 76, 1641-1645.

Kai T, Yamazaki T, Arai S, Miyazaki T. Stabilization and augmentation of circulating AIM in mice by synthesized IgM-Fc. PLoS One. 2014, 9, e97037.

Martinez VG, Escoda-Ferran C, Tadeu Simões I, Arai S, Orta Mascaró M, Carreras E, Martínez-Florensa M, Yelamos J, Miyazaki T, Lozano F. The macrophage soluble receptor AIM/Api6/CD5L displays a broad pathogen recognition spectrum and is involved in early response to microbial aggression. Cell Mol Immunol. 2014, 11, 343-354.

Hamada M, Nakamura M, Tran MT, Moriguchi T, Hong C, Ohsumi T, Dinh TT, Kusakabe M, Hattori M, Katsumata T, Arai S, Nakashima K, Kudo T, Kuroda E, Wu CH, Kao PH, Sakai M, Shimano H, Miyazaki T, Tontonoz P, Takahashi S. MafB promotes atherosclerosis by inhibiting foam-cell apoptosis. Nat Commun. 2014, 5, 3147.

Arai S, Miyazaki T. Impacts of the apoptosis inhibitor of macrophage (AIM) on obesity-associated inflammatory diseases. Semin Immunopathol. 2014, 36, 3-12.

Uramatsu T, Nishino T, Obata Y, Sato Y, Furusu A, Koji T, Miyazaki T, Kohno S. Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with nephrosclerosis: possible mechanisms of action of olmesartan and azelnidipine. Biol Pharm Bull. 2013, 36, 1271-1277.

A-Gonzalez N, Guillen JA, Gallardo G, Diaz M, de la Rosa JV, Hernandez IH, Casanova-Acebes M, Lopez F, Tabraue C, Beceiro S, Hong C, Lara PC, Andujar M, Arai S, Miyazaki T, Li S, Corbi AL, Tontonoz P, Hidalgo A, Castrillo A. The Nuclear receptor LXRα controls the functional specialization of splenic macrophages. Nat Immunol. 2013, 14, 831-839.

Nakashima K, Arai S, Suzuki A, Nariai Y, Urano T, Nakayama M, Ohara O, Yamamura K, Yamamoto K, Miyazaki T. PAD4 regulates proliferation of multipotent haematopoietic cells by controlling c-myc expression. Nat Commun. 2013, 4, 1836.

Arai S, Maehara N, Iwamura Y, Honda S, Nakashima K, Kai T, Ogishi M, Morita K, Kurokawa J, Mori M, Motoi Y, Miyake K, Matsuhashi N, Yamamura K, Ohara O, Shibuya A, Wakeland EK, Li QZ, Miyazaki T. Obesity-associated autoantibody production requires AIM to retain IgM immune complex on follicular dendritic cells. Cell Rep. 2013, 3, 1187-1198.

Kojima J, Araya J, Hara H, Ito S, Takasaka N, Kobayashi K, Fujii S, Tsurushige C, Numata T, Ishikawa T, Shimizu K, Kawaishi M, Saito K, Kamiya N, Hirano J, Odaka M, Morikawa T, Hano H, Arai S, Miyazaki T, Kaneko Y, Nakayama K, Kuwano K. Apoptosis inhibitor of macrophage (AIM) expression in alveolar macrophages in COPD. Respir Res. 2013, 14, 30.

Geng S, Matsushima H, Okamoto T, Yao Y, Lu R, Page K, Blumenthal RM, Ward NL, Miyazaki T, Takashima A. Emergence, origin, and function of neutrophil-dendritic cell hybrids in experimentally induced inflammatory lesions in mice. Blood. 2013, 121, 1690-1700.

Matsushima H, Geng S, Lu R, Okamoto T, Yao Y, Mayuzumi N, Kotol PF, Chojnacki BJ, Miyazaki T, Gallo RL, Takashima A. Neutrophil differentiation into a unique hybrid population exhibiting dual phenotype and functionality of neutrophils and dendritic cells. Blood. 2013, 121, 1677-1689.

Iwamura Y, Mori M, Nakashima K, Mikami T, Murayama K, Arai S, Miyazaki T. Apoptosis inhibitor of macrophage (AIM) diminishes lipid droplet-coating proteins leading to lipolysis in adipocytes. Biochem Biophys Res Commun. 2012, 422, 476-481.

Li C, Mannoor K, Inafuku M, Taniguchi T, Inamine Y, Miyazaki T, Watanabe H. Protective function of an unconventional γδ T cell subset against malaria infection in apoptosis inhibitor deficient mice. Cell Immunol. 2012, 279, 151-159.

Mori M, Kimura H, Iwamura Y, Arai S, Miyazaki T. Modification of N-glycosylation modulates the secretion and lipolytic function of apoptosis inhibitor of macrophage (AIM). FEBS Lett. 2012, 586, 3569-3574.

Miyazaki T, Kurokawa J, Arai S. AIMing at metabolic syndrome. -Towards the development of novel therapies for metabolic diseases via apoptosis inhibitor of macrophage (AIM). Circ J. 2011, 75, 2522-2531.

Mori M, Kitazume M, Ose R, Kurokawa J, Koga K, Osuga Y, Arai S, Miyazaki T. Death effector domain-containing protein (DEDD) is required for uterine decidualization during early pregnancy in mice. J Clin Invest. 2011, 121, 318-327.

Kurokawa J, Nagano H, Ohara O, Kubota N, Kadowaki T, Arai S, Miyazaki T. Apoptosis inhibitor of macrophage (AIM) is required for obesity-associated recruitment of inflammatory macrophages into adipose tissue. Proc Natl Acad Sci U S A. 2011, 108, 12072-12077.

Kurabe N, Mori M, Kurokawa J, Taniguchi K, Aoyama H, Atsuda K, Nishijima A, Odawara N, Harada S, Nakashima K, Arai S, Miyazaki T. The death effector domain-containing DEDD forms a complex with Akt and Hsp90, and supports their stability. Biochem Biophys Res Commun. 2010, 391, 1708-1713.

Matsushima H, Ogawa Y, Miyazaki T, Tanaka H, Nishibu A, Takashima A. Intravital imaging of IL-1beta production in skin. J Invest Dermatol. 2010, 130, 1571-1580.

Kurokawa J, Arai S, Nakashima K, Nagano H, Nishijima A, Miyata K, Ose R, Mori M, Kubota N, Kadowaki T, Oike Y, Koga H, Febbraio M, Iwanaga T, Miyazaki T. Macrophage-derived AIM is endocytosed into adipocytes and decreases lipid droplets via inhibition of fatty acid synthase activity. Cell Metab. 2010, 11, 479-492.

Kurabe N, Arai S, Nishijima A, Kubota N, Suizu F, Mori M, Kurokawa J, Kondo-Miyazaki M, Ide T, Murakami K, Miyake K, Ueki K, Koga H, Yatomi Y, Tashiro F, Noguchi M, Kadowaki T, Miyazaki T. The death effector domain-containing DEDD supports S6K1 activity via preventing Cdk1-dependent inhibitory phosphorylation. J Biol Chem. 2009, 284, 5050-5055.

Arai S, Miyake K, Voit R, Nemoto S, Wakeland EK, Grummt I, Miyazaki T. Death-effector domain-containing protein DEDD is an inhibitor of mitotic Cdk1/cyclin B1. Proc Natl Acad Sci U S A. 2007, 104, 2289-2294.

Jayachandran R, Sundaramurthy V, Combaluzier B, Mueller P, Korf H, Huygen K, Miyazaki T, Albrecht I, Massner J, Pieters J. Survival of mycobacteria in macrophages is mediated by coronin 1-dependent activation of calcineurin. Cell. 2007, 130, 37-50.

Miyazaki T, Arai S. Two distinct controls of mitotic cdk1/cyclin B1 activity requisite for cell growth prior to cell division. Cell Cycle. 2007, 6, 1419-1425.

Koltsova EK, Ciofani M, Benezra R, Miyazaki T, Clipstone N, Zuniga-Pflucker JC, Wiest DL. Early growth response 1 and NF-ATc1 act in concert to promote thymocyte development beyond the beta-selection checkpoint. J Immunol. 2007, 179, 4694-4703.

Arai S, Shelton JM, Chen M, Bradley MN, Castrillo A, Bookout AL, Mak PA, Edwards PA, Mangelsdorf DJ, Tontonoz P, Miyazaki T. A role for the apoptosis inhibitory factor AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab. 2005, 1, 201-213.

Haks MC, Lefebvre JM, Lauritsen JP, Carleton M, Rhodes M, Miyazaki T, Kappes DJ, Wiest DL. Attenuation of gammadeltaTCR signaling efficiently diverts thymocytes to the alphabeta lineage. Immunity. 2005, 22, 595-606.

Arai S, Miyazaki T. Impaired maturation of myeloid progenitors in mice lacking novel Polycomb group protein MBT-1. EMBO J. 2005, 24, 1863-1873.

Kroll J, Shi X, Caprioli A, Liu HH, Waskow C, Lin KM, Miyazaki T, Rodewald HR, Sato TN. The BTB-kelch protein KLHL6 is involved in B-lymphocyte antigen receptor signaling and germinal center formation. Mol Cell Biol. 2005, 25, 8531-8540.

Arai S, Minjares C, Nagafuchi S, Miyazaki T. Improved experimental procedures for achieving efficient germ line transmission of nonobese diabetic (NOD)-derived embryonic stem cells. Exp Diabesity Res. 2004, 5, 219-226.

Li H, Oka Y, Tsuboi A, Yamagami T, Miyazaki T, Yusa S, Kawasaki K, Kishimoto Y, Asada M, Nakajima H, Kanato K, Nishida S, Masuda T, Murakami M, Hosen N, Kawakami M, Ogawa H, Melchers F, Kawase I, Oji Y, Sugiyama H. The lck promoter-driven expression of the Wilms tumor gene WT1 blocks intrathymic differentiation of T-lineage cells. Int J Hematol. 2003, 77, 463-470.

Takeda Y, Tachibana I, Miyado K, Kobayashi M, Miyazaki T, Funakoshi T, Kimura H, Yamane H, Saito Y, Goto H, Yoneda T, Yoshida M, Kumagai T, Osaki T, Hayashi S, Kawase I, Mekada E. Tetraspanins CD9 and CD81 function to prevent the fusion of mononuclear phagocytes. J Cell Biol. 2003, 161, 945-956.

Kuwata K, Watanabe H, Jiang S Y, Yamamoto T, Tomiyama-Miyaji C, Abo T, Miyazaki T, Naito M. AIM inhibits apoptosis of T cells and NKT cells in Corynebacterium-induced granuloma formation in mice. Am J Pathol. 2003, 162, 837-847.

Suda S, Nibuya M, Suda H, Takamatsu K, Miyazaki T, Nomura S, Kawai N. Potassium channel mRNAs with AU-rich elements and brain-specific expression. Biochem Biophys Res Commun. 2002, 291, 1265-1271.

Ito Y, Arai S, van Oers NS, Aifantis I, von Boehmer H, Miyazaki T. Positive selection by the pre-TCR yields mature CD8+ T cells. J Immunol. 2002, 169, 4913-4919.

Haruta I, Kato Y, Hashimoto E, Minjares C, Kennedy S, Uto H, Yamauchi K, Kobayashi M, Yusa S, Muller U, Hayashi N, Miyazaki T. Association of AIM, a novel apoptosis inhibitory factor, with hepatitis via supporting macrophage survival and enhancing phagocytotic function of macrophages. J Biol Chem. 2001, 276, 22910-22914.

Miyazaki T, Ohura T, Kobayashi M, Shigematsu Y, Yamaguchi S, Suzuki Y, Hata I, Aoki Y, Yang X, Minjares C, Haruta I, Uto H, Ito Y, Muller U. Fatal propionic acidemia in mice lacking propionyl-CoA carboxylase and its rescue by postnatal, liver-specific supplementation via a transgene. J Biol Chem. 2001, 276, 35995-35999.

Miyazaki T, Campbell KS. Analysis and use of mutant mice exhibiting natural killer cell defects. Methods Mol Biol. 2000, 121, 323-335.

Yusa S, Ohnishi S, Onodera T, Miyazaki T. AIM, a murine apoptosis inhibitory factor, induces strong and sustained growth inhibition of B lymphocytes in combination with TGF-beta1. Eur J Immunol. 1999, 29, 1086-1093.

Miyazaki T, Hirokami Y, Matsuhashi N, Takatsuka H, Naito M. Increased susceptibility of thymocytes to apoptosis in mice lacking AIM, a novel murine macrophage-derived soluble factor belonging to the scavenger receptor cysteine-rich domain superfamily. J Exp Med. 1999, 189, 413-422.

Miyazaki T, Lemonnier FA. Modulation of thymic selection by expression of an immediate-early gene, early growth response 1 (Egr-1). J Exp Med. 1998, 188, 715-723.

Wolf PR, Tourne S, Miyazaki T, Benoist C, Mathis D, Ploegh HL. The phenotype of H-2M-deficient mice is dependent on the MHC class II molecules expressed. Eur J Immunol. 1998, 28, 2605-2618.

Tourne S, Miyazaki T, Oxenius A, Klein L, Fehr T, Kyewski B, Benoist C, Mathis D. Selection of a broad repertoire of CD4+ T cells in H-2Ma0/0 mice. Immunity. 1997, 7, 187-195.

Tourne S, Miyazaki T, Wolf P, Ploegh H, Benoist C, Mathis D. Functionality of major histocompatibility complex class II molecules in mice doubly deficient for invariant chain and H-2M complexes. Proc Natl Acad Sci U S A. 1997, 94, 9255-9260.

Miyazaki T, Muller U, Campbell KS. Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. EMBO J. 1997, 16, 4217-4225.

Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, Shibuya M, Makuuchi M, Yazaki Y, Ohnishi S. Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol. 1997, 27, 854-861.

Miyazaki T. Two distinct steps during thymocyte maturation from CD4-CD8- to CD4+CD8+ distinguished in the early growth response (Egr)-1 transgenic mice with a recombinase-activating gene-deficient background. J Exp Med. 1997, 186, 877-885.

Miyazaki T, Dierich A, Benoist C, Mathis D. Independent modes of natural killing distinguished in mice lacking Lag3. Science. 1996, 272, 405-408.

Miyazaki T, Wolf P, Tourne S, Waltzinger C, Dierich A, Barois N, Ploegh H, Benoist C, Mathis D. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell. 1996, 84, 531-541.

Miyazaki T, Dierich A, Benoist C, Mathis D. LAG-3 is not responsible for selecting T helper cells in CD4-deficient mice. Int Immunol. 1996, 8, 725-729.

Tashiro F, Kasuga A, Shimada A, Ishii M, Takei I, Miyazaki T, Yamamura K, Miyazaki J. Resistance to cyclophosphamide-induced diabetes in transgenic NOD mice expressing I-Ak. Autoimmunity. 1994, 17, 181-188.

Doi T, Higashino K, Kurihara Y, Wada Y, Miyazaki T, Nakamura H, Uesugi S, Imanishi T, Kawabe Y, Itakura H, Yazaki Y, Matsumoto A, Kodama T. Charged collagen structure mediates the recognition of negatively charged macromolecules by macrophage scavenger receptors. J Biol Chem. 1993, 268, 2126-2133.

Miyazaki T, Suzuki G, Yamamura K. The role of macrophages in antigen presentation and T cell tolerance. Int Immunol. 1993, 5, 1023-1033.

Yamamura K, Miyazaki T, Uno M, Toyonaga T, Miyazaki J. Non-obese diabetic transgenic mouse. Springer Semin Immunopathol. 1992, 14, 115-125.

Yamamura K, Miyazaki T, Uno M, Miyazaki J. Transgenic mouse as a tool for the study of autoimmune disease: insulin-dependent diabetes mellitus. Int J Immunopharmacol. 1992, 14, 451-455.

Uno M, Miyazaki T, Uehira M, Nishimoto H, Kimoto M, Miyazaki J, Yamamura K. Complete prevention of diabetes in transgenic NOD mice expressing I-E molecules. Immunol Lett. 1992, 31, 47-52.

Miyazaki T, Matsuda Y, Toyonaga T, Miyazaki J, Yazaki Y, Yamamura K. Prevention of autoimmune insulitis in nonobese diabetic mice by expression of major histocompatibility complex class I Ld molecules. Proc Natl Acad Sci U S A. 1992, 89, 9519-9523.

Miyazaki T, Uno M, Uehira M, Kikutani H, Kishimoto T, Kimoto M, Nishimoto H, Miyazaki J, Yamamura K. Direct evidence for the contribution of the unique I-ANOD to the development of insulitis in non-obese diabetic mice. Nature. 1990, 345, 722-724.